Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial

Journal:
The Lancet
Published:
Affiliations:
20
Authors:
22
Institutions Authors Share
Incyte, United States of America (USA)
4.050000
0.18
Leeds Teaching Hospitals NHS Trust (LTHT), United Kingdom (UK)
1.050000
0.05
Centre Paul Strauss, France
1.050000
0.05
City of Hope, United States of America (USA)
1.050000
0.05
Centre Antoine-Lacassagne (CAL), France
1.050000
0.05
Institut du Cancer de Montpellier (ICM), France
1.050000
0.05
Castle Hill Hospital, Hull University Teaching Hospitals NHS Trust, United Kingdom (UK)
1.050000
0.05
Centre Léon Bérard (CLB), France
1.050000
0.05
The Royal Marsden NHS Foundation Trust, United Kingdom (UK)
1.050000
0.05
Christie Hospital, United Kingdom (UK)
1.050000
0.05
Toulouse University Hospital (CHU-Toulouse), France
1.050000
0.05
AP-HP Pitié-Salpêtrière Hospital, France
1.050000
0.05
Hospital Timone, France
1.050000
0.05
IRCCS National Cancer Institute (INT) Milan, Italy
1.050000
0.05
Hôpital Pontchaillou, France
1.050000
0.05
Flinders University, Australia
1.050000
0.05
Santa Maria delle Croci Hospital, Italy
0.550000
0.03
Hospital Clinic of Barcelona, Spain
0.550000
0.03
Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD), Spain
0.550000
0.03
University of Bologna (UNIBO), Italy
0.550000
0.03